FindTrial
Sign In

Is Addition of Immune Checkpoint Inhibitors to Chemotherapy plus Bevacizumab Effective in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of Randomized Controlled Study

Is Addition of Immune Checkpoint Inhibitors to Chemotherapy plus Bevacizumab Effective in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of Randomized Controlled Study - Is Addition of Immune Checkpoint Inhibitors to Chemotherapy plus Bevacizumab Effective in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of Randomized Controlled Study

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000057763
Enrollment
Unknown
Registered
2025-05-03
Start date
2025-04-16
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic and/or unresectable colorectal cancer

Interventions

None listed

Sponsors

Nippon Medical School
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (i) diagnosed as metastatic and/or unresectable colorectal cancer, (ii) RCTs comparing cytotoxic chemotherapy plus bevacizumab with or without immune check point inhibitor

Exclusion criteria

Exclusion criteria: Studies investigating pediatric patients, animal studies, and not evaluating predefined outcomes were excluded.

Design outcomes

Primary

MeasureTime frame
progression-free survival—

Secondary

MeasureTime frame
overall survival, objective response rate, and serious adverse event—

Countries

Japan

Contacts

Public ContactAkihisa Matsuda

Nippon Medical School Gastroenterological Surgery

a-matsu@nms.ac.jp0338222131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026